
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
Orakl Oncology travaille sur une large cohorte d’organoïdes dérivés de patients (PDO) afin de prédire les résultats cliniques et de réduire les risques des essais cliniques. Nous recherchons un.e Technicien.ne de Laboratoire dynamique et motivé.e pour nous aider à développer nos capacités de culture cellulaire et nos plateformes expérimentales. Dans ce poste, vous serez amené.e à :
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
60,000+
Open Roles
500+
New This Week
| Company |
|---|
Atouts supplémentaires